Patents Issued in September 8, 2016
-
Publication number: 20160256557Abstract: Injectable pharmaceutical compositions containing 6,9-bis[(2-aminoethyl)amino]benzo[g]isoquinoline-5,10-dione dimaleate as active ingredient in the form of a lyophilised powder with a carrier selected from lactose and dextran, mixed with sodium chloride.Type: ApplicationFiled: November 10, 2015Publication date: September 8, 2016Inventors: Alberto Bernareggi, Valeria Livi
-
Publication number: 20160256558Abstract: In one aspect, the present invention provides a composition of a covalent conjugate of a GABA analog with a drug. In another aspect, the present invention provides methods for treating pain and neurological disorders using the conjugates of GABA analogs.Type: ApplicationFiled: October 9, 2015Publication date: September 8, 2016Inventor: Feng Xu
-
Publication number: 20160256559Abstract: A compound composed of a phospholipid and basic amino acid residues is provided as is a sterically stabilized phospholipid nanocarrier containing the compound and use of the same in passive and targeted delivery of negatively charged therapeutic agents encapsulated within the nanocarrier.Type: ApplicationFiled: March 4, 2016Publication date: September 8, 2016Applicant: The Board of Trustees of the University of IllinoisInventors: Hayat Onyuksel, Fatima A. Khaja
-
Publication number: 20160256560Abstract: An environmentally sensitive membrane binding polypeptide, pH (low)-sensitive membrane peptide (pHLIP) has improved insertion kinetics balanced with solubility to selectively target acidic tissues.Type: ApplicationFiled: March 18, 2016Publication date: September 8, 2016Inventors: Yana K. Reshetnyak, Oleg A. Andreev, Donald M. Engelman
-
Publication number: 20160256561Abstract: Conjugates of specific PBD dimers with an antibody that that binds to HER2, the antibody comprising a VH domain having the sequence according to SEQ ID NO. 1.Type: ApplicationFiled: October 10, 2014Publication date: September 8, 2016Inventors: Philip Wilson Howard, Patricius Hendrikus Cornelis Van Berkel
-
Publication number: 20160256562Abstract: The present invention concerns improved methods and compositions for preparing SN-38 conjugates of proteins or peptides, preferably immunoconjugates of antibodies or antigen-binding antibody fragments. More preferably, the SN-38 is attached to the antibody or antibody fragment using a CL2A linker, with 1-12, more preferably 6 or less, most preferably 1-5 SN-38 moieties per antibody or antibody fragment. Most preferably, the immunoconjugate is prepared in large scale batches, with various modifications to the reaction scheme to optimize yield and recovery in large scale. Other embodiments concern optimized dosages and/or schedules of administration of immunoconjugate to maximize efficacy for disease treatment and minimize side effects of administration.Type: ApplicationFiled: May 23, 2016Publication date: September 8, 2016Inventors: Serengulam V. Govindan, Jonathan B. Gale, Nicholas J. Holman, David M. Goldenberg
-
Publication number: 20160256563Abstract: Antibody drug conjugates (ADC's) that bind to 161P2F10B protein are described herein. 161P2F10B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.Type: ApplicationFiled: March 15, 2016Publication date: September 8, 2016Inventors: Michael TORGOV, Robert Kendall MORRISON, Aya JAKOBOVITS, Jean GUDAS, Zili AN
-
Publication number: 20160256564Abstract: The present disclosure relates to compositions and methods of killing cells. In particular examples, the method includes contacting a cell having a cell surface protein with a therapeutically effective amount of an antibody-IR700 molecule, wherein the antibody specifically binds to the cell surface protein, such as a tumor-specific antigen on the surface of a tumor cell. The cell is subsequently irradiated, such as at a wavelength of 660 to 740 nm at a dose of at least 1 J cm?2. The cell is also contacted with one or more therapeutic agents (such as an anti-cancer agent), for example about 0 to 8 hours after irradiating the cell, thereby killing the cell. Also provided are methods of imaging cell killing in real time, using fluorescence lifetime imaging. Also provided are wearable devices that include an article of clothing, jewelry, or covering; and an NIR LED incorporated into the article, which can be used with the disclosed methods.Type: ApplicationFiled: September 28, 2015Publication date: September 8, 2016Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Hisataka Kobayashi, Peter Choyke
-
Publication number: 20160256565Abstract: In this invention, composite polymeric barrier membrane is developed for clinical applications related to guided tissue regeneration and guided bone regeneration. The compositions of this polymeric membrane have conventional mechanical functions of a barrier membrane and will enable space maintenance and stabilization of the healing surgical wound. In addition, this composite polymeric membrane comprise dynamic bioactive components for dual drug delivery that will enable sustained delivery of drugs, growth factors or relevant molecules for promoting wound healing and tissue regeneration.Type: ApplicationFiled: March 2, 2015Publication date: September 8, 2016Inventor: Manoj Muthukuru
-
Publication number: 20160256566Abstract: In order to reduce the side effects of paclitaxel derivatives having excellent anti-cancer effects, an attempt was made to produce a liposome encapsulating paclitaxel derivatives such as paclitaxel monoglycosides and docetaxel monoglycosides. However, the introduction efficiency of paclitaxel derivatives, etc., into a liposome was poor, and this technique was not developed to a practical level. The present invention provides a method for producing a liposome encapsulating a paclitaxel monoglycoside and/or a docetaxel monoglycoside, and having an antibody specifically recognizing a cancer cell, the method comprising a step of bringing a liposome encapsulating a polyoxyethylene ester derivative, a lower alcohol, and a buffer or water into contact with a solution in which a paclitaxel monoglycoside and/or a docetaxel monoglycoside is dissolved in an alkylene glycol-containing buffer or water.Type: ApplicationFiled: March 22, 2013Publication date: September 8, 2016Applicants: ENSUIKO SUGAR REFINING CO., LTD., NATIONAL UNIVERSITY CORPORATION OKAYAMA UNIVERSITYInventors: Hiroki HAMADA, Ichiro FUJIWARA, Masaharu SENO, Tomonari KASAI, Tsukasa SHIGEHIRO, Masaharu MURAKAMI, Katsuhiko MIKUNI
-
Publication number: 20160256567Abstract: The present invention provides compositions comprising mRNA molecules encapsulated within lipid particles. The compositions are useful, for example, to introduce the mRNA molecules into a human subject where they are translated to produce a polypeptide that functions to ameliorate one or more symptoms of a disease. The invention also provided cationic lipids that are useful for preparing the compositions of the invention.Type: ApplicationFiled: May 12, 2016Publication date: September 8, 2016Applicant: PROTIVA BIOTHERAPEUTICS, INC.Inventors: James HEYES, Lorne R. PALMER, Stephen P. REID, Edward D. YAWORSKI, Ian MACLACHLAN, Mark WOOD, Alan D. MARTIN
-
Publication number: 20160256568Abstract: The present invention provides compositions comprising mRNA molecules encapsulated within lipid particles. The compositions are useful, for example, to introduce the mRNA molecules into a human subject where they are translated to produce a polypeptide that functions to ameliorate one or more symptoms of a disease. The invention also provided cationic lipids that are useful for preparing the compositions of the invention.Type: ApplicationFiled: May 12, 2016Publication date: September 8, 2016Applicant: PROTIVA BIOTHERAPEUTICS, INC.Inventors: James HEYES, Lorne R. PALMER, Stephen P. REID, Edward D. YAWORSKI, Ian MACLACHLAN, Mark WOOD, Alan D. MARTIN
-
Publication number: 20160256569Abstract: Block copolymers containing charged blocks or chemical moieties sensitive to oxidation or hydrolysis have been developed. We describe the use of such block copolymers in supramolecular structures, e.g., micelles or vesicles, and pharmaceutical compositions and in methods of preparing the supramolecular structures and pharmaceutical compositions. The invention is particularly useful for the delivery of pharmaceutical agents, e.g., nucleic acids, to cells.Type: ApplicationFiled: February 5, 2016Publication date: September 8, 2016Inventors: James Brandon DIXON, Jeffrey A. HUBBELL, Conlin P. O'NEIL, Melody SWARTZ, Diana VELLUTO
-
Publication number: 20160256570Abstract: The present invention provides methods comprising the in vivo delivery of small nucleic acid molecules capable of mediating RNA interference and reducing the expression of myostatin, wherein the small nucleic acid molecules are introduced to a subject by systemic administration. Specifically, the invention relates to methods comprising the in vivo delivery of short interfering nucleic acid (siNA) molecules that target a myostatin gene expressed by a subject, wherein the siNA molecule is conjugated to a lipophilic moiety, such as cholesterol. The myostatin siNA conjugates that are delivered as per the methods disclosed are useful to modulate the in vivo expression of myostatin, increase muscle mass and/or enhance muscle performance. Use of the disclosed methods is further indicated for treating musculoskeletal diseases or disorders and/or diseases or disorders that result in conditions in which muscle is adversely affected.Type: ApplicationFiled: November 10, 2014Publication date: September 8, 2016Applicant: SIRNA THERAPEUTICS, INC.Inventors: Marija Tadin-Strapps, Tayeba Khan, Walter Richard Strapps, Laura Sepp-Lorenzino, Vasant Jadhav, Duncan Brown
-
Publication number: 20160256571Abstract: The present invention concerns a neuroglobin agonist for use in the treatment or prevention of a mitochondrial disease associated with respiratory chain complex I (RCCI) deficiency and/or respiratory chain complex III (RCCIII) deficiency.Type: ApplicationFiled: September 30, 2013Publication date: September 8, 2016Inventors: Marisol CORRAL-DEBRINSKI, Christopher LECHAUVE, Jose-Alain SAHEL, Thomas DEBEIR
-
Publication number: 20160256572Abstract: Provided are formulations, compositions, kits and methods for delivering biological moieties such as modified nucleic acids into cells to induce, reduce or modulate protein expression in non-human vertebrates.Type: ApplicationFiled: April 1, 2016Publication date: September 8, 2016Inventors: Noubar B. Afeyan, Gregory J. Sieczkiewicz, Stephane Bancel
-
Publication number: 20160256573Abstract: The invention provides compositions and methods for effecting wound healing in a mammal, where the compositions include therapeutic mRNA which incorporate modified nucleosides and nucleotides.Type: ApplicationFiled: April 15, 2016Publication date: September 8, 2016Inventors: Antonin de Fougerolles, Stephane Bancel
-
Publication number: 20160256574Abstract: A method and apparatus for determining physiological data related to an animal, such as kidney diagnostics data, is provided. The method includes injecting a mixture of a first and a second molecule into an animal (e.g., a human patient), determining a molecular ratio of the molecules, and determining the physiological data based on the molecular ratio. The apparatus includes a number of finger receiving apertures, a light generation circuit, a light detection circuit, a pulse counting circuit, and a user interface.Type: ApplicationFiled: May 16, 2016Publication date: September 8, 2016Inventors: Weiming YU, Bruce A. MOLITORIS, Ruben M. SANDOVAL
-
Publication number: 20160256575Abstract: Applicants have discovered a novel induction method for inducing digital dermatitis lesions consistent with the natural disease process. Applicants have prepared a consortium including a macerated tissue culture that may be used in the method as well as a novel inoculation procedure. The consortia of microbes includes isolates of Treponema phagedenis, Porphorymonas, and Baceteroides and the invention includes use of these novel isolates in preventing and treating digital dermatitis. The invention can be used to screen, test or compare the relative efficacy of various drugs and biologics for use in treatment or control of digital dermatitis.Type: ApplicationFiled: March 7, 2016Publication date: September 8, 2016Inventors: Paul Joseph Plummer, Adam Krull, Jan Shearer, Patrick Gorden
-
Publication number: 20160256576Abstract: The present invention provides a method of optical electrophysiological probing, including: providing a fluorescing chemical probe; contacting a thick portion of tissue with the fluorescing chemical probe to create a thick portion of treated tissue; applying a first range of wavelengths of electromagnetic radiation to the treated portion of tissue; and detecting a plurality of depth-specific emission wavelengths emitted from the thick portion of treated tissue.Type: ApplicationFiled: May 19, 2016Publication date: September 8, 2016Inventors: Arkady M. Pertsov, Arvydas Matiukas, Leslie M. Loew, Joseph P. Wuskell
-
Publication number: 20160256577Abstract: The present invention relates to radiolabeled LPA1 receptor antagonists or pharmaceutically acceptable salts thereof which are useful for the quantitative imaging of LPA1 receptors in mammals.Type: ApplicationFiled: October 31, 2014Publication date: September 8, 2016Inventors: Thomas Jon Seiders, David J. Donnelly, Samuel J. Bonacorsi, JR., Kai Cao, Tritin Tran, Adrienne Pena, Joonyoung Kim, Richard E. Carson, Nabel Nabulsi, Jean-Dominique Gallezot, Yiyun Huang, Jeffrey Roger Roppe
-
Publication number: 20160256578Abstract: The present invention provides a diagnostic agent for a therapeutic effect on cancer, containing a compound represented by formula (1-0). (In formula (1-0), R represents —O(CH2)n—, —O(CH2)nOC2H4—, —CH2O(CH2)n—, or —CH2O(CH2)nOC2H4—, n represents an integer of 1 to 5, and Q1 represents F or —OCH3.Type: ApplicationFiled: September 18, 2014Publication date: September 8, 2016Applicant: Hamamatsu Photonics K.K.Inventors: Hideo TSUKADA, Masakatsu KANAZAWA, Norihiro HARADA, Shingo NISHIYAMA
-
Publication number: 20160256579Abstract: A method for labeling a prostate-specific membrane antigen (PSMA) ligand with a radioactive isotope, such as 68Ga, 177Lu, or 90Y, includes providing a reaction vial containing a sodium-based buffering agent and the PSMA ligand, both in dried form; adding a solution of the radioactive isotope in HCl to the reaction vial, thus obtaining a solution of the PSMA ligand and the radioactive isotope in the HCl; and mixing the solution and then incubating it for a sufficient period of time, thus reacting the PSMA ligand with the radioactive isotope to thereby obtain the PSMA ligand labeled with the radioactive isotope, At least 90% of the radioactive isotope in the solution is bound to the PSMA ligand. A kit can be used for carrying out the method. Radiolabeled PSMA ligands prepared by this method can be used for both imaging and therapy.Type: ApplicationFiled: March 2, 2016Publication date: September 8, 2016Inventor: Eli Shalom
-
Publication number: 20160256580Abstract: A gastrin analogue shows high uptake in CCK-2 receptor positive tumors and simultaneously a very low accumulation in the kidneys. This is achieved by a mini-gastrin analogue PP-F11 having the formula: PP-F11-X-DGlu-DGlu-DGlu-DGlu-DGlu-DGlu-Ala-Tyr-Gly-Trp-Y-Asp-Phe-NH2, wherein Y is an amino acid replacing methionine and X is a chemical group attached to the peptide for diagnostic and/or therapeutic intervention at CCK-2 receptor relevant diseases. Very suitable compounds with respect to a high tumor to kidney ratio are mini-gastrin analogues with six D-glutamic acids or six glutamines. These compounds still possess a methionine which can be oxidized easily which is a disadvantage for clinical application under GMP due to the forms which may occur. The elimination of the methionine leads to a lower affinity to oxidation which in general favors the tumor-kidney-ratio. Ideally, the methionine is replaced by norleucine.Type: ApplicationFiled: October 23, 2014Publication date: September 8, 2016Inventors: MARTIN BEHE, ROGER SCHIBLI
-
Publication number: 20160256581Abstract: A method of synthesizing a radiolabeled nanoparticle. The method includes heating a solution including an iron oxide nanoparticle and at least one radioactive metal ion to bind the iron oxide nanoparticle and the at least one radioactive metal ion, thereby forming the radiolabeled nanoparticle. The method further includes adding a quenching agent to the solution to complex with non-bound radioactive metal ions remaining in the solution. The method further includes separating the complexed quenching agent from the radiolabeled nanoparticle.Type: ApplicationFiled: October 9, 2014Publication date: September 8, 2016Inventors: Jason Philip Holland, Lee Josephson
-
Publication number: 20160256582Abstract: Dialysis monitors capable of storing and using thermal energy and methods related thereto are disclosed. Dialysis monitors capable of storing and using disinfection and/or cleaning fluids which was used at an earlier disinfection and/or cleaning event and methods related thereto are also disclosed. Thermally stored energy may, for example, be used for quick thermal disinfection of the fluid path, quick start-up of the preparation of treatment fluid, and as back-up power for continuous preparation of treatment fluid should externally provided power be interrupted.Type: ApplicationFiled: November 11, 2014Publication date: September 8, 2016Inventors: Thomas HERTZ, Sture HOBRO, Lennart JONSSON
-
Publication number: 20160256583Abstract: The deodorizing filter 1 of the present invention is provided with a deodorizing fiber layer 10 which contains a fiber 11 and a chemical adsorption type deodorant 13 bonded to a surface of the fiber 11, and a thickness of the deodorizing fiber layer 10 is 0.3 mm or more, a basis weight of the deodorizing fiber layer 10 is in a range from 30 to 100 g/m2, and a permeability measured by fragile form method is in a range from 50 to 350 cm3/(cm2·s).Type: ApplicationFiled: August 28, 2014Publication date: September 8, 2016Applicant: TOAGOSEI CO., LTD.Inventor: Yoshinao YAMADA
-
Publication number: 20160256584Abstract: The disclosed compositions and methods aid in controlling or eliminating many common odors and bacteria and enzymes that cause odor. Odors are controlled or eliminated by bringing the compositions into contact or proximity with the odors. The compositions are stored in an absorbent carrier which is then placed in a position where it will come into contact with the odor or the source of the odor. The compositions stored in the absorbent material can be fully hydrated for use or hydrated and then dehydrated for use. The disclosed compositions comprise a biocidal system comprising one or more primary biocides, one or more pH buffers, and one or more surfactants. The composition may be placed in an aqueous solution.Type: ApplicationFiled: March 4, 2016Publication date: September 8, 2016Inventors: John W. Veenstra, Benny McKee
-
Publication number: 20160256585Abstract: Technologies are generally described for positionable air freshener devices. The devices may comprise an insertion section. The insertion section may include electrodes effective to receive and conduct an electric current and secure the device to an electric source. The insertion section may include a ball. The devices may comprise a base. The base may include a socket. The socket may attach to the ball. The socket and ball may form a ball joint. The base may include a port effective to receive electric current from the electrodes. The base may include a collar effective to apply heat sufficient to release a fragrance from a material when electrical current is supplied to the collar from the electrodes. The device may include a cap with a ring shaped cross-section, sized and shaped so as to be connectable to the base such that the port is accessible when the cap is connected.Type: ApplicationFiled: May 16, 2016Publication date: September 8, 2016Inventor: ALFRED ESSES
-
Publication number: 20160256586Abstract: The invention provides a volatile material dispenser having a housing and an implement which is operatively associated with the housing. The implement is configured to be movable between a first position and a second position, wherein the implement is configured to retain a first refill when the implement is in the first position, and wherein the implement is configured to retain a second refill when the implement is in the second position, and wherein the first and second refills have different features. The dispenser may include a heater and a visual indicating system. The invention further provides a method of converting the volatile material dispenser for use between the first refill and the second refill, and a method of retaining one of the refills in the volatile material dispenser.Type: ApplicationFiled: March 6, 2015Publication date: September 8, 2016Inventors: Jason R. Eastcott, Sheng Zhou
-
Publication number: 20160256587Abstract: An emanator device for emanating an air treatment agent into the surrounding air comprises a housing which contains a solid or liquid source of the air treatment agent, wherein the housing comprises a blister or capsule containing an air treatment agent and a plurality of openings which are sufficiently small that they can be closed by a film or plug of water. For example the openings may be provided by a gauze or mesh. The openings do not inhibit the emanation of air treatment agent released from the blister, but when the emanator device is subject to wet conditions, as may happen in a dishwashing machine, the openings are blocked by a film or plug of water. The air treatment agent does not therefore enter the water, where it may have caused adverse effects, or simply have been wasted. Under dry conditions, however, emanation occurs normally.Type: ApplicationFiled: May 12, 2016Publication date: September 8, 2016Inventor: Mauro Davanzo
-
Publication number: 20160256588Abstract: Wearable devices for dispensing insect repellents, fragrances, and/or other chemicals along the outside of the clothing of a human are disclosed. They are of the type that are clipped onto a belt or the like, and use a powered fan to dispense active. They are configured with fan rotor arrangements to minimize power use while still achieving acceptable air flow rates. These changes permit use of smaller batteries and more compact arrangements for battery positioning. This in turn permits a much more compact and lightweight construction to achieve the desired results. The devices are also provided with a rotatable clip structure to render use of the device more comfortable when the user is seated and to provide greater control over the direction of the dispensing. Further, they are provided with modified lids to facilitate active refill replacement.Type: ApplicationFiled: May 16, 2016Publication date: September 8, 2016Applicant: S. C. Johnson & Son, Inc.Inventors: Saleh A. Saleh, David C. Belongia, Nitin Sharma, Paul E. Furner, Kwamena Gyakye degraft-Johnson, Raymund J. Alfaro, Donald J. Schumacher
-
Publication number: 20160256589Abstract: A system for dispensing liquids comprising: a reservoir containing a fluid, a wick which is in contact with the fluid, and, an ultrasonic atomizer, wherein a portion of the wick in contact with the ultrasonic atomizer. The wick is made from an inorganic material which is preferably metal, and is in contact with the ultrasonic atomizer in a spring-like manner.Type: ApplicationFiled: September 22, 2014Publication date: September 8, 2016Inventor: Tsafrir SASSON
-
Publication number: 20160256590Abstract: A vehicle air purification system has a photocatalyst activated by photons emitted via an ultraviolet light emitting diode (UV-LED). The photocatalyst on a supporting structure is positioned to contact airflow passing through or over the photocatalyst. Chemical contaminants and microorganisms are eliminated from the airflow that makes contact with the photocatalyst structure.Type: ApplicationFiled: March 8, 2016Publication date: September 8, 2016Inventor: Fariborz TAGHIPOUR
-
Publication number: 20160256591Abstract: A sanitary napkin for external use is described, comprising a total surface which is provided with a useful surface, which has a nano silver treated layer, an anionic strip and an absorbent polymeric band. Said sanitary napkin has a length between 140 mm and 380 mm. Said anionic strip has a stable concentration of negative ions per cubic centimeters between 4100 and 8000, over an area between 3% and 34% of the total surface, and between 7% and 34% of the useful surface.Type: ApplicationFiled: October 13, 2014Publication date: September 8, 2016Applicant: HNP S.R.L.Inventor: Michele GRILLI
-
Publication number: 20160256592Abstract: Stretch laminate hot melt adhesives and stretch laminates are described. The stretch laminate hot melt adhesives are suitable for adhering elastic materials with inelastic substrates, and allow permanent deformation of the inelastic substrate and extensions and retractions of the elastic materials. The stretch laminate hot melt adhesive is particularly suitable for back ear lamination for disposable absorbent articles.Type: ApplicationFiled: March 1, 2016Publication date: September 8, 2016Inventors: Torsten LINDNER, Matthias MORAND, Robert Haines TURNER, Ebrahim REZAI, Marc HAMM, Jinyu CHEN, Yuhong HU, Andy SWAIN, Jennifer THATCHER
-
Publication number: 20160256593Abstract: Provided is a wound dressing prepared from whole blood that is clotted ex vivo to form a sheet of clotted blood that is applied onto the skin over a sight of skin injury.Type: ApplicationFiled: November 5, 2015Publication date: September 8, 2016Inventors: Alon Kushnir, Igal Kushnir
-
Publication number: 20160256594Abstract: The present invention relates to a pharmaceutical composition in form of emulsion or microemulsion and the use thereof as aid during endoscopic procedures in which it is injected in a target tissue in order to form a cushion. More in details, the invention relates to a method for performing an endoscopic procedure, which comprises injecting said pharmaceutical composition in form of emulsion or microemulsion in a target tissue of a patient, in order to form a cushion, which cushion is then optionally subjected to an endoscopic surgical procedure, such as a resection.Type: ApplicationFiled: May 13, 2016Publication date: September 8, 2016Applicant: COSMO TECHNOLOGIES LTD.Inventors: Luigi MORO, Luigi Maria LONGO, Enrico FRIMONTI, Alessandro REPICI
-
Publication number: 20160256595Abstract: The present invention relates to an isocyanate functional prepolymer that can be achieved through a) a reaction of an H functional starter compound having at least one Zerewitinoff active H atom with an alkylene oxide and a comonomer to a preliminary stage bearing hydroxyl groups, wherein said comonomer is selected from the group comprising lactides, glycolides, cyclical dicarboxylic acid anhydrides as well as combinations thereof and wherein said comonomer is integrated through statistical copolymerization into the polymer chain(s) of the preliminary stage bearing hydroxyl groups, and b) a reaction of the preliminary stage bearing hydroxyl groups from step a) with a polyfunctional isocyanate to an isocyanate functional prepolymer. The invention additionally relates to a process for producing this isocyanate functional prepolymer, a tissue adhesive system containing such an isocyanate functional prepolymer and a dispensing system having at least two chambers and this type of tissue adhesive system.Type: ApplicationFiled: May 16, 2016Publication date: September 8, 2016Inventors: Heike Heckroth, Christoph Eggert, Jõrg Hofmann, Klaus Lorenz
-
Publication number: 20160256596Abstract: Methods, compositions, and kits for adhering polymers and other materials to another material, and in particular to bone or bone-like structures or surfaces. A composition of matter includes a urethane dimethacrylate-methyl methacrylate copolymer with a plurality of first polymer regions based on urethane dimethacrylate and a plurality of second polymer regions based on methyl methacrylate. The method includes placing an orthopedic joint implant having an attachment surface in a joint space, applying a first non-urethane-containing precursor, a second urethane-containing precursor, and a initiator to the attachment surface; contacting the first and second precursors and the initiator with the joint surface; and copolymerizing the first and second precursors and forming an adhesive copolymer and attaching the implant to the joint.Type: ApplicationFiled: October 7, 2015Publication date: September 8, 2016Inventors: Lampros KOURTIS, David MYUNG, Daniel CHANG, Bing YU, Timothy SUN, Michael J. JAASMA, Vernon HARTDEGEN
-
Publication number: 20160256597Abstract: Provided, among other things, is a method of treating a wound comprising: periodically applying to the wound over a course of days an effective amount of a water based formulation (comprising: 0.5 to 5 wt % of an emollient comprising silicone oil, 2 to 10 wt % of fatty acid, humectant(s), emulsifying agent(s), and polymer(s)), wherein the formulation is formulated as a spray, cream, lotion, milk or foam-former.Type: ApplicationFiled: May 16, 2016Publication date: September 8, 2016Inventors: Christopher N. Hensby, Mats Silvander
-
Publication number: 20160256598Abstract: An implant for implantation into a body is provided with a surface that is provided for contact with the body or a bodily fluid when implanted and which surface has a first surface charge when in a first state. The surface assumes a second state having a second surface charge as a result of surface treatment, the second surface charge being a lower positive surface charge or a higher negative surface charge than the first surface charge. The implant is used for regulating an adsorption of proteins on the surface of the implant in terms of type, quantity and/or conformation of certain proteins by means of a defined second state of the surface, which has a defined second surface charge and/or a defined predetermined composition of an oxide layer of the surface.Type: ApplicationFiled: November 12, 2014Publication date: September 8, 2016Inventors: Arik ZUCKER, Stefano BUZZI, Armin W. MÄDER, Vincent MILLERET, Martin EHRBAR, Algirdas ZIOGAS
-
Publication number: 20160256599Abstract: A shape memory polymer (SMP) intraocular lens may have a refractive index above 1.45, a Tg between 10° C. and 60° C., inclusive, de minimis or an absence of glistening, and substantially 100% transmissivity of light in the visible spectrum. The intraocular lens is then rolled at a temperature above Tg of the SMP material. The intraocular device is radially compressed within a die to a diameter of less than or equal to 1.8 mm while maintaining the temperature above Tg. The compressed intraocular lens device may be inserted through an incision less than 2 mm wide in a cornea or sclera or other anatomical structure. The lens can be inserted into the capsular bag, the ciliary sulcus, or other cavity through the incision. The SMP can substantially achieve refractive index values of greater than or equal to 1.Type: ApplicationFiled: May 17, 2016Publication date: September 8, 2016Inventors: Malik Y. Kahook, Naresh Mandava, Robin Shandas, Bryan Rech
-
Publication number: 20160256600Abstract: A shape memory polymer (SMP) intraocular lens may have a refractive index above 1.45, a Tg between 10° C. and 60° C., inclusive, de minimis or an absence of glistening, and substantially 100% transmissivity of light in the visible spectrum. The intraocular lens is then rolled at a temperature above Tg of the SMP material. The intraocular device is radially compressed within a die to a diameter of less than or equal to 1.8 mm while maintaining the temperature above Tg. The compressed intraocular lens device may be inserted through an incision less than 2 mm wide in a cornea or sclera or other anatomical structure. The lens can be inserted into the capsular bag, the ciliary sulcus, or other cavity through the incision. The SMP can substantially achieve refractive index values of greater than or equal to 1.Type: ApplicationFiled: May 17, 2016Publication date: September 8, 2016Inventors: Malik Y. Kahook, Naresh Mandava, Robin Shandas, Bryan Rech
-
Publication number: 20160256601Abstract: A shape memory polymer (SMP) intraocular lens may have a refractive index above 1.45, a Tg between 10° C. and 60° C., inclusive, de minimis or an absence of glistening, and substantially 100% transmissivity of light in the visible spectrum. The intraocular lens is then rolled at a temperature above Tg of the SMP material. The intraocular device is radially compressed within a die to a diameter of less than or equal to 1.8 mm while maintaining the temperature above Tg. The compressed intraocular lens device may be inserted through an incision less than 2 mm wide in a cornea or sclera or other anatomical structure. The lens can be inserted into the capsular bag, the ciliary sulcus, or other cavity through the incision. The SMP can substantially achieve refractive index values of greater than or equal to 1.Type: ApplicationFiled: May 17, 2016Publication date: September 8, 2016Inventors: Malik Y. Kahook, Naresh Mandava, Robin Shandas, Bryan Rech, Michael D. Lowery, Daniel Urbaniak
-
Publication number: 20160256602Abstract: A solidifying prepolymeric implant composition comprising a biocompatible prepolymer and an optional filler. One such implant composition is a polyurethane implant composition comprising an isocyanate, such as hydroxymetbylenediisocyanate (HMDI) and an alcohol, such as polycaprolactonediol (PCL diol). The compositions of the invention are useful for improving bone structure in patients by applying the solidifying implant composition to bone, reinforcing bone structure, improving load bearing capacity and/or aiding healing of microfractures.Type: ApplicationFiled: May 17, 2016Publication date: September 8, 2016Inventors: Jeffrey A. D'Agostino, Andrew J. Carter, Craig M. Jones, Arthur C. Watterson
-
Publication number: 20160256603Abstract: The invention relates to medicine and specifically to combustiology, to surgery, and to cosmetology and can be used as a bioplastic material for replacing defects in epithelial tissues (protecting against evaporation and infection) and for stimulating regeneration. The technical result is increased efficacy in healing wounds. The goal is achieved in that a histo-equivalent bioplastic material is used which includes a substrate in the form of a matrix, the material for which is a native form of hyaluronic acid, distinguished in that the histo-equivalent bioplastic material contains a 1.5% solution of hyaluronic acid and a 5% solution of a peptide complex which are mixed until a viscous elastic gel is formed, situated in the foundation and subjected to ultraviolet photopolymerization in a biosafety cabinet over the course of 5-7 hours at the following quantitative ratio in ml: 1.Type: ApplicationFiled: September 12, 2013Publication date: September 8, 2016Inventors: Olga Ivanovna Burlutskaya, Ramil Rafailevich Rakhmatullin, Tatyana Ivanovna Burtseva, Abay Izhbulatovich Adelshin
-
Publication number: 20160256604Abstract: The present invention provides, among other things, a elastomeric biomaterial having enzymatically cross-linked amino acid phenolic side chains to generate highly elastic hydrogels. Materials are characterized by tunable mechanical properties, gelation kinetics and swelling properties of these new protein polymers. Provided materials are support encapsulation of cells. Methods of making and using of provided particles are also disclosed.Type: ApplicationFiled: October 6, 2014Publication date: September 8, 2016Inventors: Craig W. Hanna, Benjamin P. Partlow, David L. Kaplan
-
Publication number: 20160256605Abstract: Materials and methods are provided to direct the formation of new lymphatics and to reconnect the disrupted lymphatic network. These materials and methods enable to improve survival of lymph nodes and lymph node fragments and their integration into a lymphatic network, following lymph node and lymph node fragments transplantation. The treatment or prevention of lymphedema is also addressed. In certain embodiments, a bundle of fibers or fibrils presented in the composition is effective to stimulate and direct the formation of new lymphatic and blood vessels. The bundle of fibers or fibrils presented in the composition is effective to promote survival of the lymph node or lymph node fragments and integration of the lymph node or lymph node fragments into a lymphatic network in the mammalian subject, at the site of transfer or transplantation.Type: ApplicationFiled: October 10, 2014Publication date: September 8, 2016Inventors: Catarina Hadamitzky, Tatiana Zaitseva, Michael V. Paukshto
-
Publication number: 20160256606Abstract: The present disclosure provides tissue products produced from adipose-containing tissues, as well as methods for producing such tissue products. The tissue products can comprise decellularized and partially de-fatted tissues. In addition, the present disclosure provides systems and methods for using such products.Type: ApplicationFiled: May 19, 2016Publication date: September 8, 2016Inventors: Wenquan Sun, Xianghong Liu